中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 37 Issue 8
Aug.  2021
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2021  >  37(8): 1841-1847

Efficacy and safety of CalliSpheres microsphere versus conventional transcatheter arterial chemoembolization in treatment of hepatocellular carcinoma: A Meta-analysis

DOI: 10.3969/j.issn.1001-5256.2021.08.019
  • a.

    Department of General Surgery (Hepatobiliary Surgery), The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, China

  • b.

    Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, China

  • c.

    Academician (Expert) Working of Sichuan Province, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, China

Research funding:

National Natural Science Foundation of China (81802778);

Chengdu High-tech Zone Medical Association 2020 Special Research Fund for Interventional Cancer (2020S02)

  • Received Date: 2020-12-16
  • Accepted Date: 2021-01-19
  • Published Date: 2021-08-20
    Abstract
  •   Objective  To investigate the efficacy and safety of CalliSpheres microsphere-transcatheter arterial chemoembolization (CSM-TACE) versus conventional transcatheter arterial chemoembolization (cTACE) in the treatment of hepatocellular carcinoma (HCC) through a meta-analysis.  Methods  PubMed, Web of Science, Cochrane Library, CNKI, Wanfang Data, and VIP were searched for all Chinese and English articles on the application of CSM-TACE and cTACE in HCC published up to the end of October, 2020. After quality assessment was performed for the articles included, RevMan 5.3 software provided by Cochrane Library was used for analysis.  Results  A total of 15 studies were included, with 1535 patients in total. This meta-analysis showed that compared with the patients receiving cTACE, the patients receiving CSM-TACE had significantly higher 1-year overall survival rate (odds ratio [OR]=2.26, 95% confidence interval [CI]: 1.63-3.13, P < 0.000 01), 2-year overall survival rate (OR=1.73, 95%CI: 1.20-2.50, P=0.003), and 2-year progression-free survival rate (OR=1.60, 95%CI: 1.05-2.43, P=0.03). In terms of safety, compared with the patients receiving cTACE, the patients receiving CSM-TACE had significantly lower incidence rates of postoperative vomiting (OR=0.65, 95%CI: 0.46-0.92, P=0.01), bone marrow suppression (OR=0.17, 95%CI: 0.05-0.54, P=0.003), and neutropenia (OR=0.18, 95%CI: 0.07-0.45, P=0.000 3), while there were no significant differences between the two groups of patients in postoperative pyrexia, abdominal pain, and ascites (all P > 0.05).  Conclusion  CSM-TACE has significant advantages in improving 1- and 2-year overall survival rates and 2-year progression-free survival rates and can significantly reduce the incidence rates of postoperative vomiting, bone marrow suppression, and neutropenia. Therefore, CSM-TACE is a safe and effective treatment method.

     

    • FullText(HTML)
  • loading
    • References(35)
  • [1]
    SINGAL AG, LAMPERTICO P, NAHON P. Epidemiology and surveillance for hepatocellular carcinoma: New trends[J]. J Hepatol, 2020, 72(2): 250-261. DOI: 10.1016/j.jhep.2019.08.025.
    [2]
    ZHOU M, WANG H, ZENG X, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet, 2019, 394(10204): 1145-1158. DOI: 10.1016/S0140-6736(19)30427-1.
    [3]
    Chinese College of Interventionalists, Chinese Medical Doctor Association. Chinese clinical practice guidelines for transarterial chemoembolization of hepatocellular carcinoma[J]. J Intervent Radiol, 2018, 27(12): 1117-1126. DOI: 10.3969/j.issn.1008-794X.2018.12.001.

    中国医师协会介入医师分会. 中国肝细胞癌经动脉化疗栓塞治疗(TACE)临床实践指南[J]. 介入放射学杂志, 2018, 27(12): 1117-1126. DOI: 10.3969/j.issn.1008-794X.2018.12.001.
    [4]
    de BAERE T, ARAI Y, LENCIONI R, et al. Treatment of liver tumors with lipiodol TACE: Technical recommendations from experts opinion[J]. Cardiovasc Intervent Radiol, 2016, 39(3): 334-343. DOI: 10.1007/s00270-015-1208-y.
    [5]
    PESAPANE F, NEZAMI N, PATELLA F, et al. New concepts in embolotherapy of HCC[J]. Med Oncol, 2017, 34(4): 58. DOI: 10.1007/s12032-017-0917-2.
    [6]
    LEE EW, KHAN S. Recent advances in transarterial embolotherapies in the treatment of hepatocellular carcinoma[J]. Clin Mol Hepatol, 2017, 23(4): 265-272. DOI: 10.3350/cmh.2017.0111.
    [7]
    NAMUR J, CITRON SJ, SELLERS MT, et al. Embolization of hepatocellular carcinoma with drug-eluting beads: Doxorubicin tissue concentration and distribution in patient liver explants[J]. J Hepatol, 2011, 55(6): 1332-1338. DOI: 10.1016/j.jhep.2011.03.024.
    [8]
    ZHOU GH, HAN J, SUN JH, et al. Efficacy and safety profile of drug-eluting beads transarterial chemoembolization by CalliSpheresⓇ beads in Chinese hepatocellular carcinoma patients[J]. BMC Cancer, 2018, 18(1): 644. DOI: 10.1186/s12885-018-4566-4.
    [9]
    WU B, ZHOU J, LING G, et al. CalliSpheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma: A short-term efficacy and safety study[J]. World J Surg Oncol, 2018, 16(1): 69. DOI: 10.1186/s12957-018-1368-8.
    [10]
    HUANG WH, FENG GS. Clinical analysis of polyvinyl alcohol callispheres in interventional embolization therapy for primary hepatocellular carcinoma[J]. J Pract Oncol, 2020, 35(3): 260-264. DOI: 10.13267/j.cnki.syzlzz.2020.03.014.

    黄文浩, 冯广森. 聚乙烯醇载药微球介入栓塞治疗原发性肝癌的临床分析[J]. 实用肿瘤杂志, 2020, 35(3): 260-264. DOI: 10.13267/j.cnki.syzlzz.2020.03.014.
    [11]
    PARMAR MK, TORRI V, STEWART L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints[J]. Stat Med, 1998, 17(24): 2815-2834. DOI: 10.1002/(sici)1097-0258(19981230)17:24<2815::aid-sim110>3.0.co;2-8.
    [12]
    JADAD AR, MOORE RA, CARROLL D, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary?[J]. Control Clin Trials, 1996, 17(1): 1-12. DOI: 10.1016/0197-2456(95)00134-4.
    [13]
    MA Y, ZHAO C, ZHAO H, et al. Comparison of treatment efficacy and safety between drug-eluting bead transarterial chemoembolization with CalliSpheresⓇ microspheres and conventional transarterial chemoembolization as first-line treatment in hepatocellular carcinoma patients[J]. Am J Transl Res, 2019, 11(12): 7456-7470.
    [14]
    ZHANG ZS, LI HZ, MA C, et al. Conventional versus drug-eluting beads chemoembolization for infiltrative hepatocellular carcinoma: A comparison of efficacy and safety[J]. BMC Cancer, 2019, 19(1): 1162. DOI: 10.1186/s12885-019-6386-6.
    [15]
    XIAO YD, MA C, ZHANG ZS, et al. Safety and efficacy assessment of transarterial chemoembolization using drug-eluting beads in patients with hepatocellular carcinoma and arterioportal shunt: A single-center experience[J]. Cancer Manag Res, 2019, 11: 1551-1557. DOI: 10.2147/CMAR.S193948.
    [16]
    XIANG H, LONG L, YAO Y, et al. CalliSpheres drug-eluting bead transcatheter arterial chemoembolization presents with better efficacy and equal safety compared to conventional TACE in treating patients with hepatocellular carcinoma[J]. Technol Cancer Res Treat, 2019, 18: 1533033819830751. DOI: 10.1177/1533033819830751.
    [17]
    LI H, WU F, DUAN M, et al. Drug-eluting bead transarterial chemoembolization (TACE) vs conventional TACE in treating hepatocellular carcinoma patients with multiple conventional TACE treatments history: A comparison of efficacy and safety[J]. Medicine (Baltimore), 2019, 98(21): e15314. DOI: 10.1097/MD.0000000000015314.
    [18]
    DUAN XH, JU SG, HAN XW, et al. Arsenic trioxide-eluting Callispheres beads is more effective and equally tolerant compared with arsenic trioxide/lipiodol emulsion in the transcatheter arterial chemoembolization treatment for unresectable hepatocellular carcinoma patients[J]. Eur Rev Med Pharmacol Sci, 2020, 24(3): 1468-1480. DOI: 10.26355/eurrev_202002_20206.
    [19]
    LIANG B, XIANG H, MA C, et al. Comparison of chemoembolization with CalliSpheres(Ⓡ) microspheres and conventional chemoembolization in the treatment of hepatocellular carcinoma: A multicenter retrospective study[J]. Cancer Manag Res, 2020, 12: 941-956. DOI: 10.2147/CMAR.S187203.
    [20]
    ZHOU SJ, WU BL, ZHOU J, et al. Short-term efficacy and safety of drug-eluting beads transarterial chemoembolization in the treatment of advanced primary hepatocellular carcinoma[J]. Med J Wuhan Univ, 2019, 40(5): 742-746. DOI: 10.14188/j.1671-8852.2018.1170.

    周素军, 吴宝林, 周军, 等. 药物缓释微球肝动脉化疗栓塞术治疗中晚期原发性肝癌的近期疗效及安全性分析[J]. 武汉大学学报(医学版), 2019, 40(5): 742-746. DOI: 10.14188/j.1671-8852.2018.1170.
    [21]
    WANG Z, LIU QY, YANG W, et al. Clinical value of transarterial chemoembolization with CalliSpheres drug-eluting beads manufactured in China in treatment of unresectable liver cancer[J]. Chin Hepatol, 2019, 24(7): 767-770. DOI: 10.3969/j.issn.1008-1704.2019.07.014.

    王忠, 刘启榆, 杨伟, 等. 国产CalliSpheres载药微球DEB-TACE治疗无法手术肝癌的临床价值[J]. 肝脏, 2019, 24(7): 767-770. DOI: 10.3969/j.issn.1008-1704.2019.07.014.
    [22]
    PU CY, CHEN Q. Application of drug-eluting beads in transarterial chemoembolization for advanced liver cancer and its effect on immune function[J]. Chin Hepatol, 2020, 25(1): 42-46. DOI: 10.3969/j.issn.1008-1704.2020.01.015.

    蒲长宇, 陈琦. 载药微球用于中晚期肝癌TACE术对肝功能及免疫功能的影响[J]. 肝脏, 2020, 25(1): 42-46. DOI: 10.3969/j.issn.1008-1704.2020.01.015.
    [23]
    LIU JF, DUAN XH, REN JZ, et al. Comparative effect of CalliSpheres drug loading microspheres and lipiodol transarterial chemoembolization in the treatment of huge primary liver cancer[J]. Chin J Hepatol, 2019, 27(6): 460-462. DOI: 10.3760/cma.j.issn.1007-3418.2019.06.014.

    刘娟芳, 段旭华, 任建庄, 等. CalliSpheres载药微球与碘油经导管动脉化疗栓塞治疗原发性巨块型肝癌的疗效对比[J]. 中华肝脏病杂志, 2019, 27(6): 460-462. DOI: 10.3760/cma.j.issn.1007-3418.2019.06.014.
    [24]
    LI FY, SUN YM, SHI MB. Value of drug-eluting beads versus ultra-fluid lipiodol in transarterial chemoembolization for liver cancer[J]. Mod Digest Interv, 2020, 25(5): 649-652. DOI: 10.3969/j.issn.1672-2159.2020.05.022.

    李富永, 孙玉敏, 石明波. 载药微球及超液化碘油用于肝癌肝动脉栓塞术的价值比较[J]. 现代消化及介入诊疗, 2020, 25(5): 649-652. DOI: 10.3969/j.issn.1672-2159.2020.05.022.
    [25]
    CHEN G, ZHANG D, YING YC, et al. Clinical investigation on transarterial chemoembolization with indigenous drug-eluting beads in treatment of unresectable hepatocellular carcinoma[J]. J Zhejiang Univ(Med Sci), 2017, 46(1): 44-51. DOI: 10.3785/j.issn.1008-9292.2017.02.07.

    陈刚, 张鼎, 应亚草, 等. 国产载药微球经动脉化疗栓塞治疗不可切除原发性肝癌的临床研究[J]. 浙江大学学报(医学版), 2017, 46(1): 44-51. DOI: 10.3785/j.issn.1008-9292.2017.02.07.
    [26]
    HA Y, LEE JB, SHIM JH, et al. Validation and reappraisal of the assessment for retreatment with transarterial chemoembolization score for unresectable non-metastatic hepatocellular carcinoma in a hepatitis B virus-endemic region[J]. Eur Radiol, 2016, 26(10): 3510-3518. DOI: 10.1007/s00330-015-4185-2.
    [27]
    GOLFIERI R, GIAMPALMA E, RENZULLI M, et al. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma[J]. Br J Cancer, 2014, 111(2): 255-264. DOI: 10.1038/bjc.2014.199.
    [28]
    MEMON K, KULIK L, LEWANDOWSKI RJ, et al. Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times[J]. Gastroenterology, 2011, 141(2): 526-535. DOI: 10.1053/j.gastro.2011.04.054.
    [29]
    YIN WL, LIAN J, XIAO SX, et al. Clinical effect of drug-eluting beads and conventional transcatheter arterial chemoembolization in treatment of unre-sectable liver cancer: A meta-analysis[J]. J Clin Hepatol, 2019, 35(6): 1270-1275. DOI: 10.3969/j.issn.1001-5256.2019.06.018.

    尹伟利, 连佳, 肖时湘, 等. 载药微球与传统碘化油经肝动脉化疗栓塞术治疗不可切除肝癌效果比较的Meta分析[J]. 临床肝胆病杂志, 2019, 35(6): 1270-1275. DOI: 10.3969/j.issn.1001-5256.2019.06.018.
    [30]
    CHEN P, YUAN P, CHEN B, et al. Evaluation of drug-eluting beads versus conventional transcatheter arterial chemoembolization in patients with unresectable hepatocellular carcinoma: A systematic review and meta-analysis[J]. Clin Res Hepatol Gastroenterol, 2017, 41(1): 75-85. DOI: 10.1016/j.clinre.2016.05.013.
    [31]
    JIANG S, LI GJ, ZHOU ZQ, et al. Interventional chemoembolization with CalliSpheres-loaded microspheres for the treatment of advanced hepatocellular carcinoma[J/CD]. Chin J Inter Rad(Electronic Edition), 2017, 5(3): 174-178. DOI: 10.3877/cma.j.issn.2095-5782.2017.03.013.

    姜松, 李桂杰, 周祝谦, 等. CalliSpheres载药栓塞微球治疗中晚期肝癌临床效果评价[J/CD]. 中华介入放射学电子杂志, 2017, 5(3): 174-178. DOI: 10.3877/cma.j.issn.2095-5782.2017.03.013.
    [32]
    XIE XC, ZHAO W, FAN HJ, et al. Safety and efficacy analysis of CalliSpheres drug-eluting beads TACE in the treatment of advanced liver cancer[J]. J Pract Radiol, 2020, 36(5): 792-795. DOI: 10.3969/j.issn.1002-1671.2020.05.026.

    谢璇丞, 赵卫, 范宏杰, 等. CalliSpheres载药微球动脉化疗栓塞术治疗中晚期肝癌的安全性及有效性分析[J]. 实用放射学杂志, 2020, 36(5): 792-795. DOI: 10.3969/j.issn.1002-1671.2020.05.026.
    [33]
    HONG K, KHWAJA A, LIAPI E, et al. New intra-arterial drug delivery system for the treatment of liver cancer: Preclinical assessment in a rabbit model of liver cancer[J]. Clin Cancer Res, 2006, 12(8): 2563-2567. DOI: 10.1158/1078-0432.CCR-05-2225.
    [34]
    TAYLOR RR, TANG Y, GONZALEZ MV, et al. Irinotecan drug eluting beads for use in chemoembolization: In vitro and in vivo evaluation of drug release properties[J]. Eur J Pharm Sci, 2007, 30(1): 7-14. DOI: 10.1016/j.ejps.2006.09.002.
    [35]
    LAMMER J, MALAGARI K, VOGL T, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: Results of the PRECISION V study[J]. Cardiovasc Intervent Radiol, 2010, 33(1): 41-52. DOI: 10.1007/s00270-009-9711-7.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(10)  / Tables(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (714) PDF downloads(66) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return